Qian Yufan, Chu Genglei, Zhang Lei, Wu Zhikai, Wang Qiuyuan, Guo Jiong Jiong, Zhou Feng
Department of Orthopaedics, The First Affiliated Hospital of Soochow University, No. 899 Ping Hai Road, Suzhou, Jiangsu, China.
Orthopedic Institute, Medical College, Soochow University, Suzhou, Jiangsu, China.
J Nanobiotechnology. 2024 Feb 19;22(1):72. doi: 10.1186/s12951-024-02336-4.
Osteoarthritis (OA) is one of the most prevalent chronic musculoskeletal diseases among the elderly population. In this study, macrophage-derived exosomes were isolated and identified. Exosomes were subjected to microRNA (miRNA) sequencing and bioinformatic analysis, and differentially expressed miRNAs were verified. miR-26b-5p target genes were confirmed through target-site mutation combined with a dual-luciferase reporter assay. The effects of miR-26b-5p on macrophage polarization and chondrocyte hypertrophy were assessed in vitro. miR-26b-5p agomir was applied to mice with OA induced by anterior cruciate ligament transection (ACLT). The therapeutic effects of miR-26b-5p were evaluated via pain behavior experiments and histological observations. In vitro, miR-26b-5p repolarized M1 macrophages to an anti-inflammatory M2 type by targeting the TLR3 signaling pathway. miR-26b-5p could target COL10A1, further inhibiting chondrocyte hypertrophy induced by M1 macrophage-conditioned medium (M1-CM). In vivo, miR-26b-5p agomir ameliorated gait abnormalities and mechanical allodynia in OA mice. miR-26b-5p treatment attenuated synovitis and cartilage degeneration, thereby delaying OA progression. In conclusion, M2 macrophage-derived exosomal miR-26b-5p could protect articular cartilage and ameliorate gait abnormalities in OA mice by targeting TLR3 and COL10A1. miR-26b-5p further affected macrophage polarization and chondrocyte hypertrophy. Thus, this exosomal miR-26b-5p-based strategy might be a potential method for OA treatment.
骨关节炎(OA)是老年人群中最常见的慢性肌肉骨骼疾病之一。在本研究中,分离并鉴定了巨噬细胞衍生的外泌体。对外泌体进行了微小RNA(miRNA)测序和生物信息学分析,并验证了差异表达的miRNA。通过靶位点突变结合双荧光素酶报告基因检测法确认了miR-26b-5p的靶基因。在体外评估了miR-26b-5p对巨噬细胞极化和软骨细胞肥大的影响。将miR-26b-5p激动剂应用于前交叉韧带横断(ACLT)诱导的骨关节炎小鼠。通过疼痛行为实验和组织学观察评估miR-26b-5p的治疗效果。在体外,miR-26b-5p通过靶向TLR3信号通路将M1巨噬细胞重新极化为抗炎M2型。miR-26b-5p可以靶向COL10A1,进一步抑制M1巨噬细胞条件培养基(M1-CM)诱导的软骨细胞肥大。在体内,miR-26b-5p激动剂改善了骨关节炎小鼠的步态异常和机械性异常疼痛。miR-26b-5p治疗减轻了滑膜炎和软骨退变,从而延缓了骨关节炎的进展。总之,M2巨噬细胞衍生的外泌体miR-26b-5p可以通过靶向TLR3和COL10A1保护关节软骨并改善骨关节炎小鼠的步态异常。miR-26b-5p进一步影响巨噬细胞极化和软骨细胞肥大。因此,这种基于外泌体miR-26b-5p的策略可能是一种潜在的骨关节炎治疗方法。